MedTrace Logo

European Registry for Hemadsorption in Sepsis With the Seraph Filter

NCT05608096 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-11-08

No results posted yet for this study

Summary

Although new techniques like extracorporeal blood purification have lately emerged, septic patients still have very high hospital mortality rates. Sepsis can be induced by either viremia, bacteriemia or in some cases both. Many studies have reported the effectiveness of different hemadsorbers, but patient sample sizes have been inadequate for definitive conclusions. Secondly, there are still no clear inclusion criteria as well as criteria for when to cease hemadsorption mostly due to immune dysregulation or cascade coagulation disorders. The aim of this observational prospective registry is to evaluate the effectiveness of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in the treatment of septic ICU patients and to evaluate which cluster of these patients should benefit most with this therapy.

Conditions

  • Sepsis
  • Acute Respiratory Distress Syndrome
  • Infections - Pathogen Unspecified
  • Disease
  • Critical Illness
  • Multi Organ Failure
  • Systemic Inflammatory Response Syndrome

Interventions

DEVICE

Hemoperfusion

Commercial membrane for extracorporeal blood purification (hemoperfusion)

Sponsors & Collaborators

  • Clinical Hospital Centre Zagreb

    collaborator OTHER

  • Croatian Society for Organ Support

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-25
Primary Completion
2023-06-30
Completion
2025-12-30
FDA Device
Yes

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05608096 on ClinicalTrials.gov